Summary: Materials scientists have developed a wearable, drug-free contact lens that treats depressive symptoms in mice by delivering mild electrical stimulation through the retina. The device uses targeted temporal interference to activate mood-related brain circuits non-invasively, producing effects comparable to the antidepressant fluoxetine in preclinical tests.
In a study published May 14 in Cell Reports Physical Science, researchers showed that soft, transparent contact lenses equipped with ultrathin electrodes reduced behavioral, neural, and physiological markers of depression in mice after daily 30-minute sessions for three weeks. By using the retina as an anatomical pathway into the brain, the technology selectively stimulated deep mood-regulating areas without invasive surgery or systemic medication.
Key Research Findings
- Retina as a pathway: Because the retina is an extension of the brain, the team targeted it to access interconnected mood circuits in deeper brain regions.
- Temporal interference (TI): The lenses deliver two high-frequency electrical signals that intersect and form a low-frequency interference pattern only at their overlap, enabling focused stimulation of specific deep structures while leaving the eye’s surface unaffected.
- Restored neural connectivity: Electrophysiological recordings showed recovery of connections between the hippocampus and the prefrontal cortex—pathways that commonly degrade in depression.
- Biological changes: After three weeks of daily treatment, mice exhibited a 47% rise in serotonin, a 48% drop in blood corticosterone (a stress hormone), and lower levels of inflammatory molecules in the brain.
- Comparable to Prozac: Machine learning analyses grouped treated mice with non-depressed controls, indicating efficacy similar to fluoxetine, a commonly prescribed SSRI.
Source: Cell Press
Wearable, non-drug approach to mood modulation
The soft contact lenses incorporate ultrathin electrodes made from layers of gallium oxide and platinum, designed to be flexible and optically transparent. Rather than delivering a single electrical pulse, the device uses temporal interference so that two harmless surface signals create a focused effect only where they overlap at the retina. That focal activation then follows natural visual pathways to influence brain circuits involved in mood and emotion.
“Our work opens up a new frontier for treating brain disorders through the eye,” says senior author Jang-Ung Park of Yonsei University. The team envisions a wearable, drug-free option that could expand treatments for depression and potentially other conditions such as anxiety, addiction, and cognitive decline by adapting stimulation targets.
Existing depression treatments—including pharmacotherapy, electroconvulsive therapy, and implanted stimulators—aim to modulate the same mood circuits. The novelty here is leveraging the eye’s direct anatomical link to the brain to achieve targeted stimulation non-invasively, avoiding systemic medication and surgical implants.
Previous “smart” contact lenses focused on monitoring conditions such as intraocular pressure or glucose. This study represents the first demonstration of a contact-lens-based device actively treating a brain disorder, using the retina as a minimally invasive entry point to modulate neural networks.
The research team evaluated four groups of mice: non-depressed controls, untreated depressed mice, depressed mice receiving temporal interference via the contact lens, and depressed mice treated with fluoxetine. Assessments combined behavioral tests, electrophysiological recordings, and measurements of blood and brain biomarkers linked to depression.
Mice treated with retinal temporal interference for 30 minutes per day over three weeks showed behavioral improvements on par with fluoxetine-treated animals. Brain recordings indicated restored hippocampus–prefrontal cortex connectivity, and biological assays showed reduced inflammation, lower corticosterone, and increased serotonin levels compared to untreated depressed mice.
“We observed coordinated improvements across behavior, neural activity, and biological markers, and that the overall effect matched a widely used antidepressant,” Park notes. Machine learning classification further confirmed that the treated group resembled non-depressed controls rather than untreated depressed animals.
The authors emphasize that human use will require additional development and testing. Next steps include creating a fully wireless lens, conducting long-term safety studies in larger animals, and customizing stimulation parameters per individual before progressing to clinical trials.
Funding:
This work was supported by the National Research Foundation of Korea, the Institute for Basic Science, and the Yonsei University Research Fund.
Key Questions Answered:
A: No. The stimulation is described as gentle. The temporal interference approach keeps the surface signals harmless; the focused effect only forms at the retinal intersection, creating a localized and mild activation.
A: The researchers suggest the method could be adapted to target other brain circuits, potentially offering new non-invasive treatments for anxiety, substance use disorders, and cognitive decline, though that remains to be tested.
A: They are not yet commercially available. The technology requires further safety testing in larger animals, device refinements such as wireless operation, and rigorous clinical trials in humans before any potential approval or sale.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurotech and depression research news
Author: Julia Grimmett
Source: Cell Press
Contact: Julia Grimmett – Cell Press
Image: The image is credited to Neuroscience News
Original Research: Findings published in Cell Reports Physical Science